Carl Harrington, president of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), explains the importance of Imbruvica's approval for the rare disease.
The Food and Drug Administration (FDA) granted a priority review to Yondelis to treat patients with the disease, including liposarcoma and leiomyosarcoma subtypes, who have previously received chemotherapy that included an anthracycline. The FDA will make its final approval decision within six months.
Knowing how genes and nutrients interact could likewise be the prescription for improved health.
Cancer moves fast; we need to move faster. Help make sure patients have access to important diagnostic tests.
The PD-L1 inhibitor MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer (NSCLC) that has progressed on prior therapy.
The FDA's framework for regulating lab developed tests could keep some patients from receiving validated diagnostic tests and targeted treatments like mine.
During President Barack Obama's State of the Union Address, he announced a nationwide Precision Medicine Initiative that would help cure diseases such as cancer and diabetes.
Melanoma specialist, Suzanne L. Topalian discusses how new approved drugs and those in the pipeline for advanced melanoma are making an impact for patient.
A new study has found that while the breast cancer prevention drug tamoxifen's benefits outweigh its risks, the drug isn't right for all women.
Ibrutinib becomes the first drug specifically approved for Waldenstrom's macroglobulinemia (WM), two months ahead of expectations.
Every day, breast cancer researcher Edith Perez sets her mind on finding better treatments for the disease and conducting research aimed at improving patients' lives.
When motivating people to get screened for cancer, fear may not be the best way to do it.
The Food and Drug Administration is evaluating proposals for new indications for at least 17 oncology medicines, according to Friends of Cancer Research, an advocacy group that aims to get patients cutting-edge treatments as safely and quickly as possible.
An analysis of patients with advanced hepatocellular carcinoma and elevated AFP who received second-line Cyramza showed improved survival, according to data from the phase 3 REACH study.
There is a lot of pressure on cancer patients to stay cheerful and only focus on the positive during treatment and beyond. I think this is overrated and can stifle the process of coming to terms with this disease.
Recent results from the phase 2 TERRAIN trial showed Xtandi increased progression-free survival by nearly 10 months compared with Casodex in patients with metastatic castration-resistant prostate cancer.
The integrative treatment of cancer must include nutrition as an adjunct to surgery, radiation therapy and chemotherapy.
Immune checkpoint inhibitors targeted against PD-1 and its ligand PD-L1 have rapidly advanced as treatments for patients with melanoma and non-small cell lung cancer (NSCLC), following their initial debut in 2012. What's next?
The emotional fallout of cancer takes a heavy toll. Experiencing your feelings in your own way, at your own pace, can be a challenge.
The Food and Drug Administration granted a Fast Track Designation to CPX-351 for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).
Most oncologists are well acquainted with the term precision medicine, often used interchangeably to describe a model of care in which a treatment plan is based on patient characteristics and the molecular and genetic profile of the patient's tumor.
Two recent studies outline the importance of nutrition in preventing obesity-related cancers, as well as the potential benefits of a nutrition education intervention in preventing breast cancer recurrence.
There are some things known to increase the risk of gynecologic cancers. Bottom line, being a woman puts you at risk.
Phase 2 Chinese study shows famitinib, a multi-targeted tyrosine kinase inhibitor, led to a small improvement in progression-free survival in patients with advanced, previously treated metastatic colorectal cancer.
The vastly improved outlook for patients with chronic lymphocytic leukemia (CLL) was named the American Society of Clinical Oncology's inaugural "Cancer Advance of the Year."
Last week, I walked the massive halls of Moscone West in San Francisco and attended the Gastrointestinal Cancers Symposium, better known as ASCO GI. It is a meeting I always feel quite privileged to attend; it offers a glimpse into the work, passion, and expertise that goes into the many aspects of being able to live with metastatic colon cancer.
Those of us living with metastatic cancer ride a see-saw between hope and acceptance.
Changing the administration schedule for Gemzar (gemcitabine) plus Abraxane (nab-paclitaxel) from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer, according to a retrospective study presented at the 2015 GI Cancers Symposium.
An analysis of the phase 3 NAPOLI-1 trial supports the benefits of adding MM-398 chemotherapy for the treatment of patients with metastatic pancreatic cancer who were previously treated with Gemzar.
The stress of cancer doesn't leave us at bedtime. Focusing on relaxation, rather than sleep, can get you the healing rest you need.
